Not a good buy right now: price action and trend signals are decisively bearish, with no near-term catalysts.
For an impatient trader, the setup is unattractive: expected near-term move (pattern-based) is small (~0.26% next day) while downside risk remains elevated near support.
Momentum: MACD histogram is negative (-0.0247) and negatively expanding → selling pressure is strengthening, not stabilizing.
RSI(6): ~21 (oversold/washed-out). This can produce short bounces, but oversold alone is not a buy signal when MACD is still deteriorating.
Key levels: Price 1.08 is below S1 (1.126) and close to S2 (1.024). A clean break below ~1.02 increases risk of further downside. Upside resistance starts around Pivot 1.29 then R1 1.454.
Recent tape: Regular session -9.65% with only a mild pre-market uptick (+1.75%) → no convincing reversal behavior yet.
Positive Catalysts
Oversold RSI may spark a short-term technical bounce if 1.02–1.05 support holds.
Pattern-based projection suggests potential upside over longer horizons (approx. +7.56% next week, +19.04% next month), but it is not confirmed by current momentum indicators.
No significant hedge fund or insider trend pressure reported (both neutral).
Neutral/Negative Catalysts
and sitting near the next support (S2 1.024), increasing breakdown risk.
Financial Performance
Latest quarter: 2025/Q4.
Revenue: 0 (no YoY growth; effectively no operating revenue base).
Net income: -2,228,358 (improved vs YoY, but still meaningfully negative).
EPS: -0.32 (slightly improved YoY, but still a loss).
Overall: financials show loss reduction but no revenue traction—hard to support a durable rally without a catalyst.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No recent analyst rating or price target change data provided, so a current Wall Street consensus view cannot be confirmed from the dataset.
Practical takeaway: without visible analyst support/updates and with weak trend + no catalysts, the pro-case is limited right now.
Wall Street analysts forecast EDSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDSA is 5 USD with a low forecast of 5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast EDSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDSA is 5 USD with a low forecast of 5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.120
Low
5
Averages
5
High
5
Current: 1.120
Low
5
Averages
5
High
5
H.C. Wainwright
Yi Chen
initiated
$5
AI Analysis
2025-06-27
Reason
H.C. Wainwright
Yi Chen
Price Target
$5
AI Analysis
2025-06-27
initiated
Reason
H.C. Wainwright analyst Yi Chen assumed coverage of Edesa Biotech with a Buy rating and $5 price target. Edesa is a clinical stage biopharmaceutical company primarily focused on the development of novel treatments for dermatology and respiratory indications, the analyst tells investors in a research note. The firm says the company's lead drug candidate EB06 has a favorable safety and tolerability profile for treating vitiligo.
Lucid Capital
Dev Prasad
Buy
initiated
$9
2025-05-23
Reason
Lucid Capital
Dev Prasad
Price Target
$9
2025-05-23
initiated
Buy
Reason
Lucid Capital analyst Dev Prasad initiated coverage of Edesa Biotech with a Buy rating and $9 price target. The firm has a positive outlook on the company's lead clinical asset, EB06. EB06 is a first-in-class, fully human monoclonal antibody targeting CXCL10, in development for the treatment of moderate-to-severe non-segmental vitiligo, a chronic autoimmune skin disorder with high unmet medical need, the analyst tells investors in a research note. Lucid says the mechanism of action is well-supported by a strong biological rationale. Lucid views Edesa as an attractive long-term growth opportunity, with a first-in-class asset.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EDSA
